Rexahn Pharmaceuticals, Inc. Investigation We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Rexahn Pharmaceuticals, Inc. (“REXN” or the “Company”) (NASDAQ: REXN) in connection with the proposed stock-for-stock merger of the Company with privately-held Ocuphire Pharma (“Ocuphire”). Rexahn Pharmaceuticals, Inc. Issues Mid-Year Shareholder Letter To Review Recent Progress And Clinical Plans. Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Compare. Volatility & Risk. REXN Rexahn Pharmaceuticals Inc Statement of Ownership (sc 13g) * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. Rexahn Pharmaceuticals, Inc. Rexahn is a tiny company with limited financial resources and no partner to help shoulder the burden of developing its main drugs. Rexahn Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for … ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn … About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the … About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat. Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of incorporation or organization) (I.R.S. In her most recent role, she was Director of Finance at Gemphire Therapeutics, Inc. which merged with NeuroBo Pharmaceuticals, Inc. in December of 2019. Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of incorporation or organization) (I.R.S. The combined company will do business as Ocuphire Pharma, with shares trading on the Nasdaq Capital Market under the ticker "OCUP.". Rexahn Pharmaceuticals (Filer) Form 10-Q. Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. Payout Estimate. The company belongs in the Biotechnology industry, Healthcare sector and employs people. Rexahn Pharmaceuticals, Inc. (NYSE: RNN) shares are advancing to a two-month high following an announcement from the company regarding a Chinese licensing deal. Rexahn Pharmaceuticals Inc. Dividend policy None Price as of: NOV 05, 02:46 PM EDT $1.81 -0.06 -3.21% Watchlist Overview. Rexahn Pharmaceuticals, Inc. (RNN) stock price, charts, trades & the US's most popular discussion forums. Company. General form for quarterly reports under Section 13 or 15 (d) 08/29/2019. Rexahn Pharmaceuticals is a clinical pharmaceutical company dedicated to developing and commercializing drugs for cancer, CNS … On January 19, 2011, Rexahn Pharmaceuticals, Inc. (“Rexahn”) and Teva Pharmaceutical Industries Limited, a limited liability company organized under the laws of Israel (“Teva”) entered into a second amendment (the “Second Amendment”) to the Securities Purchase Agreement, dated June 26, 2009, as amended (the “Purchase Agreement”). REXAHN PHARMACEUTICALS, INC. : Press releases relating to REXAHN PHARMACEUTICALS, INC. Investor relations | Nyse: | Nyse Employer Identification No.) Buy Rexahn Pharmaceuticals (REXN) Jing Jun Ma. Message board - Online Community of active, educated investors researching and discussing Rexahn Pharmaceuticals, Inc. Stocks. The stock has been trading in … Payout Estimate. 9/1/2017. Ocuphire Pharma plans to initiate two Phase 3 registration trials in the fourth quarter of 2020, and two Phase 2 trials in the first quarter of 2021. Payout History. Rexahn Pharmaceuticals, Inc., Rockville, Maryland. Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this … Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Company Profile. About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals Inc. (NasdaqCM: REXN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. Payout History. Free forex prices, toplists, indices and lots more. Rexahn Pharmaceuticals employs 5 staff and has a trailing 12-month revenue of around 0.00. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). A high-level overview of Ocuphire Pharma, Inc. (OCUP) stock. Among the reasons for investing now is to possibly reap the benefits of numerous catalysts in early 2015. Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat. Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) ("Rexahn") announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to … (RTTNews) - Rexahn Pharmaceuticals, Inc. (REXN), which closed Tuesday's trading at $3.66, gaining 78.54%, was one of the top gainers of the day. Rexahn Pharmaceuticals, Inc. – par value $0.0001 and Warrants to Purchase 10,750,000 Shares of Common Stock REXAHN PHARMACEUTICALS, INC. Listed Company " Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Rockville, Md.-based Rexahn Pharmaceuticals terminated a nearly two-year-old agreement with Merck that paired the company’s experimental phosphorylated-p68 inhibitor with Keytruda as a potential treatment for metastatic triple-negative breast cancer.. Rexahn disclosed the decision in a filing with the U.S. Securities and Exchange Commission this week, Seeking Alpha first reported. About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat. Rexahn Pharmaceuticals (Filer) Form 8-K. Current report pursuant to Section 13 or 15 (d) 08/29/2019. She has 18 years of finance and accounting experience, including public company, with a focus on life sciences. Phone. Choose a platform. Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. Rexahn Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Employer Identification No.) Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in … Rexahn Pharmaceuticals stocks (REXN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Rockville, Md.-based Rexahn Pharmaceuticals terminated a nearly two-year-old agreement with Merck that paired the company’s experimental phosphorylated-p68 inhibitor with Keytruda as a potential treatment for metastatic triple-negative breast cancer.. Rexahn disclosed the decision in a filing with the U.S. Securities and Exchange Commission this week, Seeking Alpha first reported. Trading Ideas. Trading Ideas. Free forex prices, toplists, indices and lots more. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. 15245 Shady Grove Road, Suite 455 Rockville, MD 20850 (Address of principal executive offices) (Zip Code) 46 likes. Yoga interventions offer promise for the treatment of major depressive disorder (MDD), yet their safety and potential impact on suicidal ideation (SI) have not been well documented. (GLOBE NEWSWIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, presented updated, preliminary data from the ongoing Phase 2a clinical trial of RX-3117 in combination with ABRAXANE ® (paclitaxel protein-bound particles for injectable … Home Dividend Stocks Health Care Biotech Pharma Biotech Rexahn Pharmaceuticals Inc. (REXN) Overview. New. Company Profile. Free forex prices, toplists, indices and lots more. Rexahn Pharmaceuticals. Rexahn Pharma up big on announced merger with Ocuphire Pharma seekingalpha.com - June 18 at 10:43 AM: Rexahn and Ocuphire Enter into Definitive Merger Agreement feeds.benzinga.com - June 18 at 12:31 AM: Rexahn Pharmaceuticals Inc. www.marketwatch.com - June 10 at 6:20 PM: Rexahn Pharmaceuticals Inc (REXN.OQ) in.reuters.com - May 23 at 11:44 PM